Related Experiment Video
Updated: Jul 18, 2026
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
Rottlerin inhibits human T cell responses
Cécile Springael1, Séverine Thomas, Souad Rahmouni
1Institute for Medical Immunology (IMI), Université Libre de Bruxelles (ULB), Rue Adrienne Bolland, 8, B-6041 Gosselies, Belgium.
Abstract:
Rottlerin is a pharmacological inhibitor of protein kinase C (PKC) theta, a novel PKC selectively expressed in T lymphocytes. PKC theta is known to regulate T cell receptor (TCR)/CD28 signalling pathways in T lymphocytes, but the impact of PKC theta inhibition on human T cell responses remains undefined. In this work, we describe the effects of rottlerin on the responses of CD4+ and CD8+ human T lymphocytes upon polyclonal activation. We observed a dose-dependent inhibition of CD4+ and CD8+ T cell proliferation in response to anti-CD3/anti-CD28 antibodies stimulation in the presence of rottlerin. This inhibition was associated with impaired CD25 expression and decreased interleukin (IL)-2 production in activated T cells. In contrast, rottlerin did not alter IL-2-induced T cell proliferation. Furthermore, we demonstrated that rottlerin blocked interferon (IFN) gamma, IL-10 and IL-13 mRNA expression in TCR/CD28 activated CD4+ T cells. These findings place rottlerin as a potent immunosuppressive agent for the development of novel therapies in T cell mediated immune disorders.
Insights
Rottlerin inhibits protein kinase C theta, suppressing T cell proliferation and cytokine production. This suggests rottlerin
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Protein kinase C (PKC) theta is crucial for T lymphocyte activation via T cell receptor (TCR)/CD28 signaling.
- The precise impact of inhibiting PKC theta on human T cell responses is not fully understood.
Purpose of the Study:
- To investigate the effects of rottlerin, a PKC theta inhibitor, on human CD4+ and CD8+ T cell responses.
- To determine rottlerin's potential as an immunosuppressive agent.
Main Methods:
- Polyclonal activation of human T lymphocytes using anti-CD3/anti-CD28 antibodies.
- Assessment of T cell proliferation, CD25 expression, and cytokine production (IL-2, IFN-gamma, IL-10, IL-13) in the presence of varying rottlerin concentrations.
- Evaluation of IL-2-induced T cell proliferation.
Main Results:
- Rottlerin demonstrated dose-dependent inhibition of CD4+ and CD8+ T cell proliferation.
- Impaired CD25 expression and reduced IL-2 production were observed in rottlerin-treated T cells.
- Rottlerin did not affect IL-2-induced T cell proliferation but blocked key cytokine mRNA expression (IFN-gamma, IL-10, IL-13).
Conclusions:
- Rottlerin effectively inhibits T cell activation and cytokine production by targeting PKC theta.
- These findings highlight rottlerin's potent immunosuppressive properties.
- Rottlerin shows promise for developing new therapies for T cell-mediated immune disorders.
Related Concept Videos
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:40Cell-mediated Immune Responses